NCT05631626View on ClinicalTrials.gov

Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

June 13, 2023

Study Completion Date

June 13, 2023

Conditions
ADHDADHD - Combined TypeAttention Deficit Hyperactivity Disorder CombinedAttention Deficit Hyperactivity Disorder
Interventions
DRUG

CTx-1301 - Dexmethylphenidate 25mg

25mg CTx-1301 (Dexmethylphenidate tablet)

DRUG

CTx-1301 - Dexmethylphenidate 37.5mg

37.5mg CTx-1301 (Dexmethylphenidate tablet)

DRUG

CTx-1301 - Dexmethylphenidate 50mg

50mg CTx-1301 (Dexmethylphenidate tablet)

DRUG

Placebo

Placebo

Trial Locations (1)

89128

Clinical Research of Southern Nevada, LLC, Las Vegas

Sponsors
All Listed Sponsors
collaborator

Rho, Inc.

INDUSTRY

lead

Cingulate Therapeutics

INDUSTRY

NCT05631626 - Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. | Biotech Hunter | Biotech Hunter